MCRB Seres Therapeutics
- 0.856
- +0.006+0.75%
Seres Therapeutics News
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Seres Therapeutics (MCRB) Receives a Buy From TD Cowen
Seres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended
Express News | Seres Therapeutics Inc - Ser-155 Shows 77% Relative Risk Reduction in Bloodstream Infections
Express News | Seres Therapeutics Inc - Ser-155 Shows Significant Decrease in Fecal Albumin and Systemic Inflammation
Express News | Seres Therapeutics Inc - Extends Cash Runway Into Q1 2026
Express News | Seres Therapeutics Announces New Translational Biomarker Results From Ser-155 Phase 1B Clinical Study and Provides Corporate Updates
Seres Therapeutics Announces New Translational Biomarker Results From SER-155 Phase 1b Clinical Study and Provides Corporate Updates
The Past Three Years for Seres Therapeutics (NASDAQ:MCRB) Investors Has Not Been Profitable
Seres Therapeutics to Present at J.P. Morgan Healthcare Conference, Highlighting SER-155 Breakthrough Therapy Designation
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
Optimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost Confidence
Seres Therapeutics' SER-155 Receives FDA Breakthrough Therapy Designation for Bloodstream Infection Reduction
Express News | Seres Therapeutics Inc - FDA Meeting on Next Study of Ser-155 Expected in Q1 2025
Express News | FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity
No Data